Abstract 217P
Background
No reliable biomarker is available for predicting worse clinical outcome in chemo-resistant urothelial carcinoma (UC) patients treated with pembrolizumab. We focused on the neutrophil-lymphocyte ratio (NLR), which is reported to be a simple index of systemic inflammation and a possible biomarker for predicting prognosis in various malignancies, including UC. Our aim was to evaluate whether a high NLR level could predict subsequent clinical outcomes in chemo-resistant UC patients treated with pembrolizumab.
Methods
We identified 74 cases treated with pembrolizumab for chemo-resistant UC between December 2017 and April 2019 at our 5 institutions. We investigated the association between NLR levels and their prognosis. We defined patients with NLR of > 3.37 as the high NLR group according to a calculation by receiver-operating curve analysis.
Results
The high NLR group consisted of 30 cases (40.5%). The 6-month progression-free survival (PFS) rate for the high NLR group was 10.0±5.5%, which was significantly lower than that for their counterpart (44.8±7.8%, p < 0.001). Multivariate Cox regression analysis revealed that elevated NLR (p < 0.001) and liver metastases (p = 0.003) were independent indicators for disease progression. Furthermore, the 6-month cancer-specific survival (CSS) rate for the high NLR group (64.5±9.1%) was significantly lower than that for their counterpart (88.8±5.3%, p = 0.004). Multivariate analysis revealed that an elevated NLR was the only independent indicator for cancer-specific death (p = 0.008). The change of NLR level before and after pembrolizumab was elevated in 46 cases. The 6-month PFS and CSS rate for the increased NLR group (17.8±6.0% and 71.9±7.3%) was significantly lower than that for their counterpart (47.0±10.6% and 90.9±6.1%, p = 0.012 and p = 0.009).
Conclusions
Elevated NLR could identify a population with a poor response to pembrolizumab treatment among chemo-resistant UC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Koichiro Ogihara.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract